Inactive Instrument

Medifocus, Inc.

Equities

MDFZF

CA58470Q1019

Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019

July 30, 2019 at 09:52 pm IST

Medifocus Inc. announced earnings results for the full year ended March 31, 2019. For the full year, the company announced total revenue was USD 2.766 million compared to USD 2.666 million a year ago. Operating loss was USD 522,589 compared to USD 721,151 a year ago. Net loss was USD 1.470 million compared to USD 1.541 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Medifocus, Inc.

Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer	22/20/22	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	03/20/03	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	30/19/30	CI
Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	29/19/29	CI
Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	30/19/30	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	28/19/28	CI
Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong	03/19/03	CI
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling	03/18/03	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018	13/18/13	CI
Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018	13/18/13	CI
Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System	05/18/05	CI
Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System	09/18/09	CI
Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017	28/17/28	CI
Medifocus, Inc. Auditor Raises 'Going Concern' Doubt	31/17/31	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	16/17/16	CI
Medifocus Inc. Reports Operating Results for the Six Months Ended September 30, 2016	19/16/19	CI
Medifocus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended September 30, 2016	08/16/08	CI
Medifocus Inc. Appoints William Jow as Chief Executive Officer to Replace Augustine Y. Cheung	03/16/03	CI
Medifocus Inc. Announces Board Changes	15/16/15	CI
Medifocus Inc. Announces Earnings Results for the First Quarter Ended June 30, 2016	15/16/15	CI
Medifocus Inc. Auditor Raises 'Going Concern' Doubt	10/16/10	CI
Medifocus Inc.(TSXV:MFS) dropped from S&P/TSX Venture Composite Index	18/16/18	CI
Medifocus Inc. Signs Research &Development and Manufacturing Agreement with Yuanxing Bio-Pharm Science &Technology Co. Ltd	13/16/13	CI
Medifocus Inc. announced that it has received $0.79 million in funding	14/15/14	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2015	07/15/07	CI

Chart Medifocus, Inc.

Duration

Period

More charts

Company Profile

Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Sector

More about the company